Increasing prevalence of diabetes, smart insulin drug delivery technologies and painless insulin drug delivery technologies

DUBLIN, September 23, 2022 /PRNewswire/ — The Global Markets for Drug and Insulin Delivery Technologies report has been added to’s The offer of

Search_and_markets logo

The current report will provide an in-depth insight into the market for insulin delivery drugs and technologies. This report analyzes drug and insulin delivery technologies market trends with data from 2021, estimates from 2022, CAGR forecasts to 2027 (forecast period 2022-2027) and regional technology markets of drugs and insulin delivery.

This report will highlight the current and future potential of the drug and insulin delivery technologies market, along with a detailed analysis of the competitive environment. The regulatory scenarios, drivers, constraints and opportunities will be covered in the current report. The report also covers market forecasts for 2026 and market share for major market players.

Drug and insulin delivery technologies are used to manage type 1 and type 2 diabetes. Convenient insulin delivery devices such as smart pens help diabetes patients optimize blood glucose control and minimize the risk of related health problems. Advanced insulin delivery devices provide better patient compliance.

Traditional insulin syringes and pumps are being replaced by reusable and disposable insulin pens due to the latter’s portability, greater dosing accuracy, built-in memory, larger doses, and ease of use. There have not been any major advances in traditional syringes and pumps.

Major manufacturers of insulin delivery devices include Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG. Major manufacturers of modern insulin and human insulin include Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim International GmbH, Biocon, and Viatris Inc.

The growth of the market is attributed to factors such as increasing incidence of diabetes and new drug and insulin delivery technologies. The global market for drug and insulin delivery technologies is segmented by device type, insulin type, and region.

In this report, the market is segmented on the basis of device type, insulin type, and geographic region. Types of devices include syringes, insulin pens, insulin pumps, smart pens, and others. Types of insulin include long-acting, rapid-acting, premixed, intermediate-acting, and short-acting insulin.

Geographical regions covered include North America, Europe, Asia-Pacific and Rest of the World (RoW). Individual countries included include the US, GermanyUnited Kingdom, Ital, France, Japan, China AND India.

Descriptive company profiles of leading manufacturers of modern insulin and insulin delivery devices, including Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG

The report includes

  • 24 data tables and 31 additional tables

  • An updated overview of the global markets for drug and insulin delivery technologies

  • Global market trends analysis, with historical market revenue (sales data) for 2020 and 2021, estimates for 2022 and CAGR forecasts up to 2027

  • Highlights of current status of insulin drug and insulin delivery industry structure, new technological updates and issues related to insulin pens and insulin syringes, ongoing research activities and regulatory and pricing scenarios

  • Current and forecast market size estimation for drug and insulin delivery technologies, and corresponding market share analysis by device type, insulin type, and geographic region

  • Up-to-date information on major merger and acquisition agreements, partnerships, collaborations and other strategic alliances within the insulin delivery technologies and drug industry

  • Market opportunity analysis with a holistic review of Porter’s Five Forces analysis model taking into account micro and macro environmental factors prevailing in the market

  • Identification of key stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues

Main topics covered:

Chapter 1 Introduction
1.1 Overview of insulin
1.2 Overview of diabetes
1.2.1 Disease symptoms and risk factors
1.2.2 Epidemiology and economic burden
1.3 Aims and objectives of the study
1.4 Reasons for doing this study
1.5 What’s new in this update?
1.6 Scope of the Report
1.7 Information sources
1.8 Methodology
1.9 Geographic breakdown
1.10 Analyst Credentials
1.11 Custom Search
1.12 Preliminary Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market dynamics
3.1 Market leaders
3.1.1 Increasing prevalence of diabetes
3.1.2 Intelligent insulin drug delivery technologies
3.1.3 Painless insulin drug delivery technologies
3.2 Market Restrictions
3.2.1 Product Withdrawals
3.3 Market Opportunities
3.3.1 Inorganic strategies among market players

Chapter 4 Market overview
4.1 Market Insights
4.1.1 Insulin
4.1.2 Diabetes
4.2 Current market trends
4.2.1 Recent Product Introductions
4.2.2 Recent strategic alliances
4.3 Future perspective

Chapter 5 Regulatory Landscape and Reimbursement Scenario
5.1 Regulatory Landscape
5.1.1 US Medical Device Regulations
5.1.2 US Drug Regulations
5.1.3 European Regulations for Medical Devices
5.1.4 European Medicines Regulations
5.1.5 Asia Pacific Medical Device Regulations
5.2 Refund Scenario
5.2.1 Summary of prices and refunds
5.2.2 Pricing and reimbursement for medical devices
5.2.3 Pricing and reimbursement for pharmaceuticals
5.3 Insurance
5.3.1 Insurance for Diabetes Emergencies

Chapter 6 Impact of Covid-19 on the market
6.1 Overview
6.2 The Covid-19 crisis
6.2.1 Market impact for drug and insulin delivery technologies
6.2.2 Covid-19 measures

Chapter 7 Market Segmentation by Device Type
7.1 Insulin delivery technologies
7.1.1 Syringes
7.1.2 Insulin pens
7.1.3 Insulin pumps
7.1.4 Smart pens
7.1.5 Other

Chapter 8 Market Breakdown by Type of Insulin
8.1 Insulin
8.1.1 Structure of Insulin
8.1.2 Biosynthesis of insulin
8.1.3 Types of insulin

Chapter 9 Market Segmentation by Region
9.1 Overview
9.1.1 North America
9.1.2 Europe
9.1.3 Asia-Pacific
9.1.4 Rest of the World

Chapter 10 Market Opportunity Analysis
10.1 Porter’s Five Forces Analysis
10.1.1 Threat of New Entrants
10.1.2 Threat of Substitutes
10.1.3 Bargaining Power of Suppliers
10.1.4 Bargaining Power of Buyers
10.1.5 Degree of Competition

Chapter 11 The competitive landscape

Chapter 12 Company Profiles
12.1 Large Companies

  • B. Braun Melsungen AG

  • Becton, Dickinson and Co.

  • Bioko

  • Boehringer Ingelheim International GmbH

  • Eli Lilly and Co.

  • F. Hoffmann-La Roche Ltd.

  • Medtronic Inc.

  • Novo Nordisk A/S

  • Sanofi

  • Viatris Inc.

  • Ypsomed Holding AG

  • Other companies

  • Cequr Simplicity

  • Debiotech Sa

  • Emperra GmbH E-Health Technologies

  • Insulet Corp.

  • Nanopass Technologies Ltd.

  • Nipro Medical Corp.

  • Owen Mumford Ltd.

  • Tandem Diabetes Care Inc.

For more information about this report visit

Media contact:

Research and markets
Laura WoodSenior manager
[email protected]

For EST office hours, call +1-917-300-0470
For US/CAN Call toll free +1-800-526-8630
For GMT office hours Call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside USA): +353-1-481-1716




View original content: drug delivery technologies–painless drug delivery technologies-insulin-301631950.html

SOURCE Research and Markets

Leave a Comment